Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628808 | 0.86 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3081056 | 0.85 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3087954 | 0.84 | ADORA2A (0.66) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL16628751 | 0.83 | CACNA1B (0.56) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3090422 | 0.81 | ADORA2A (0.65) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL3087918 | 0.80 | ADORA3 (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL16628795 | 0.80 | ADORA3 (0.66) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL16628820 | 0.79 | ADORA3 (0.68) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3093862 | 0.79 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL16628744 | 0.79 | ADORA2A (0.71) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA2A 4016/4885ADORA1 3386/4885ADORA3 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.